HeartBeam, a medical technology company trading on NASDAQ under the symbol BEAT, has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment was conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, representing a critical milestone in generating clinical data necessary to broaden the system's medical applications.
The company is developing what it describes as the first cable-free device capable of collecting electrocardiogram (ECG) signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used outside medical facilities, potentially allowing physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care remotely. The technology has already received FDA clearance for arrhythmia assessment in December 2024, with additional clearance for its 12-lead ECG synthesis software following in December 2025.
The ALIGN-ACS study represents a strategic expansion of HeartBeam's technology beyond its current arrhythmia assessment capabilities. If successful, the system could enable earlier detection of heart attacks outside traditional clinical settings, potentially reducing treatment delays that significantly impact patient outcomes. The portable nature of the device aligns with growing trends toward remote patient monitoring and decentralized healthcare delivery.
HeartBeam holds over 20 issued patents related to its technology enablement, providing intellectual property protection for its innovations. The company's progress can be tracked through its newsroom at https://ibn.fm/BEAT, where updates regarding BEAT are regularly posted. Investors and interested parties should review the full terms of use and disclaimers applicable to all content provided by the InvestorBrandNetwork at http://IBN.fm/Disclaimer.
The medical technology sector continues to see significant innovation in cardiac care, with particular emphasis on early detection and remote monitoring solutions. HeartBeam's approach to 3D ECG technology represents a novel method for capturing comprehensive cardiac data without the constraints of traditional wired systems. The potential expansion to heart attack detection could address a significant clinical need, given that timely intervention is critical for minimizing heart muscle damage and improving survival rates following myocardial infarction.
As with all medical device development, the ALIGN-ACS study represents an early stage in the regulatory pathway. The company's forward-looking statements acknowledge various risks and uncertainties that could affect actual results, including factors detailed in its SEC filings. These statements are based on information available as of the announcement date and are subject to change based on clinical outcomes, regulatory developments, and market conditions. The successful expansion of the HeartBeam System's indications could potentially transform how cardiac emergencies are detected and managed, particularly in non-clinical environments where immediate access to traditional diagnostic equipment may be limited.
